A Game-Changer for Diabetes: Polymer Delivers Insulin Painlessly Through Skin
November 25, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Cequa, Restasis, Verkazia
Synonyms :
cyclosporine ophthalmic
Class :
Ophthalmics, Other; Calcineurin Inhibitors
Brand Name :
Cequa, Restasis, Verkazia
Synonyms :
cyclosporine ophthalmic
Class :
Ophthalmics, Other; Calcineurin Inhibitors
Dosage Forms & Strength Â
Ophthalmic emulsion Â
0.05%-Restasis  Â
0.05%- Restasis Â
0.1% – Verkazia  Â
Ophthalmic solution Â
0.09%Â Â Â
Dosage Forms & Strength Â
Ophthalmic emulsion Â
0.05%-Restasis  Â
0.05%- Restasis Â
0.1% – Verkazia  Â
Ophthalmic solution Â
0.09%Â Â Â
Refer adult dosingÂ
may reduce the therapeutic effect of vaccines
poliovirus vaccine, live, trivalent
may reduce the therapeutic effect of vaccines
poliovirus vaccine inactivated
may reduce the therapeutic effect of vaccines
measles, mumps, rubella, and varicella vaccine, live (Rx)
may reduce the therapeutic effect of vaccines
measles mumps and rubella vaccine, live
may reduce the therapeutic effect of vaccines
may reduce the therapeutic effect of vaccines
smallpox (vaccinia) vaccine, live
may reduce the therapeutic effect of vaccines
may reduce the therapeutic effect of vaccines
It may diminish the serum concentration when combined with colesevelam
may have a decreased therapeutic effect when combined with covid-19 vaccine
may increase the immunosuppressive effect of tacrolimus
may decrease the therapeutic effect when combined with influenza virus vaccines
may decrease the therapeutic effect when combined with rabies vaccine
may decrease the therapeutic effect when combined with sipuleucel-t
may decrease the therapeutic effect when combined with vaccines
may have an increased immunosuppressive effect when combined with immunosuppressants
may have an increased immunosuppressive effect when combined with leflunomide
may decrease the diagnostic effect when combined with coccidioides immitis test
may decrease the therapeutic effect when combined with COVID-19 vaccine
belimumab's immunosuppressive properties reduce the efficacy of the live rotavirus oral vaccine, leading to diminished effects
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of Immunosuppressants
respiratory syncytial virus vaccine, adjuvanted
may increase the immunosuppressive effect of Immunosuppressants
respiratory syncytial virus (RSV) vaccine
may increase the immunosuppressive effect of Immunosuppressants
meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccineÂ
immunosuppressants can decrease the efficacy of the vaccines
may decrease the diagnostic effect of Immunosuppressants
may decrease the diagnostic effect of Immunosuppressants
may decrease the diagnostic effect of Immunosuppressants
may decrease the diagnostic effect of Immunosuppressants
may decrease the diagnostic effect of Immunosuppressants
may decrease the diagnostic effect of Immunosuppressants
may decrease the diagnostic effect of Immunosuppressants
may decrease the diagnostic effect of Immunosuppressants
may decrease the diagnostic effect of Immunosuppressants
may increase the immunosuppressive effect of immunosuppressive agents
may have an increased immunosuppressive effect when combined with immunosuppressants
may have an increased immunosuppressive effect when combined with baricitinib
may have an increased adverse effect when combined with dengue tetravalent vaccine
may have an increased immunosuppressive effect when combined with immunosuppressants
may increase the immunosuppressive effect of tacrolimus
may have an increased adverse effect when combined with nadofaragene firadenovec
may have an increased immunosuppressive effect when combined with natalizumab
may have an increased immunosuppressive effect when combined with immunosuppressants
may have an increased immunosuppressive effect when combined with ruxolitinib
may have an increasingly adverse effect when combined with talimogene laherparepvec
may have an increased immunosuppressive effect when combined with tofacitinib
may have an increased immunosuppressive effect when combined with upadacitinib
poliovirus vaccine, live, trivalent
may enhance the adverse/toxic effect
poliovirus vaccine inactivated
may enhance the adverse/toxic effect
measles, mumps, rubella, and varicella vaccine, live (Rx)
may enhance the adverse/toxic effect
measles mumps and rubella vaccine, live
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
smallpox (vaccinia) vaccine, live
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may have an increasingly adverse effect when combined with immunosuppressants
methotrexate can also enhance the immunosuppressive effect of tacrolimus (Topical)
may have an increasingly adverse effect when combined with typhoid vaccine
may have an increasingly adverse effect when combined with yellow fever vaccine
may have an increasingly adverse effect when combined with poliovirus vaccine
may have an increased immunosuppressive effect when combined with ritlecitinib
cladribine: they may increase the immunosuppressive effect of immunosuppressants
may decrease the therapeutic effect of immunosuppressants
may decrease the therapeutic effect of immunosuppressants
may decrease the therapeutic effect of immunosuppressants
may decrease the therapeutic effect of immunosuppressants
may decrease the therapeutic effect of immunosuppressants
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
respiratory syncytial virus vaccine, adjuvanted
may reduce the therapeutic effect of vaccines
respiratory syncytial virus (RSV) vaccine
may reduce the therapeutic effect of vaccines
respiratory syncytial virus vaccine, adjuvanted
may decrease the therapeutic effect when combined with vaccines
respiratory syncytial virus (RSV) vaccine
may decrease the therapeutic effect when combined with vaccines
may have an increased adverse effect when combined with BCG products
may have an increased immunosuppressive effect when combined with cladribine
may increase the therapeutic effect of immunosuppressants
may decrease the therapeutic effect when combined with brincidofovir
may have an increased immunosuppressive effect when combined with inebilizumab
may have an increased immunosuppressive effect when combined with ocrelizumab
may have an increased immunosuppressive effect when combined with ofatumumab
may decrease the therapeutic effect when combined with pidotimod
may have an increased immunosuppressive effect when combined with immunosuppressants
may have an increased immunosuppressive effect when combined with immunosuppressants
may have an increased immunosuppressive effect when combined with immunosuppressants
may have an increased immunosuppressive effect when combined with ublituximab
may have an increased immunosuppressive effect when combined with tacrolimus
may decrease the therapeutic effect when combined with pneumococcal vaccines
antithymocyte globulin rabbitÂ
may have an increasingly adverse effect when combined with antithymocyte globulin
leniolisib reduces the efficacy of the live rotavirus oral vaccine by exerting immunosuppressive effects
The immunosuppressive effects of obinutuzumab diminish the effectiveness of the live rotavirus oral vaccine
antithymocyte globulin equineÂ
may have an increasingly adverse effect when combined with antithymocyte globulin
respiratory syncytial virus vaccine, adjuvanted
immunosuppressants decrease the efficacy of vaccines
respiratory syncytial virus (RSV) vaccine
immunosuppressants decrease the efficacy of vaccines
may have an increased immunosuppressive effect when combined with immunosuppressants
elevated doses of corticosteroids can inhibit the delayed-type hypersensitivity (DTH) skin test response after a two-week course of treatment
typically, the response reverts to its pre-treatment level within a few weeks after discontinuing steroid therapy
may decrease the therapeutic effect when combined with covid-19 vaccine
Actions and Spectrum:Â
Actions:Â Â Â
cyclosporine is an immunosuppressant drug that works by inhibiting the activity of certain immune cells that cause inflammation. In the eye, it can reduce inflammation and help to increase tear production, which can alleviate symptoms of dry eye. Â
Spectrum:Â Â Â
cyclosporine ophthalmic is typically used to treat moderate to severe dry eye disease, which is a condition that affects the quality and/or quantity of tears. It may also be used to treat other eye conditions that involve inflammation, such as uveitis or conjunctivitis. Â
Efficacy:Â Â Â
Studies have shown that cyclosporine ophthalmic can be an effective treatment for dry eye disease, improving both the signs and symptoms of the condition. However, it may take several weeks of regular use before its full benefits are realized.Â
Frequency Defined Â
1-10%Â Â
Discharge Â
Conjunctival hyperemia Â
Epiphora Â
Foreign body sensation Â
Eye pain Â
Stinging Â
Eye pruritus (8%)Â Â
Visual disturbance Â
Ocular discomfort (6%)Â Â
Cough (5%)Â Â
Visual acuity reduced (5%)Â Â
Ocular hyperemia (4%)Â Â
Upper respiratory tract infection Â
Headache (4%)Â Â
>10%Â Â
Eye pain (12%)Â Â
Black Box Warning:Â
There is no black box warning for cyclosporine ophthalmic.Â
Contraindication/Caution:Â
cyclosporine ophthalmic is contraindicated in patients with a history of hypersensitivity to any of the components of the medication. It is also cautioned in patients with a history of herpetic keratitis and those with active ocular infections.
Additionally, caution should be exercised in patients with a history of malignancy, uncontrolled hypertension, renal impairment, and hepatic impairment.
The use of cyclosporine ophthalmic in pregnant and nursing mothers should be done with caution, and the potential risks and benefits should be weighed before administration.Â
Pregnancy warnings:    Â
Pregnancy category: N/AÂ
Lactation: Excreted into human milk is unknownÂ
Pregnancy Categories:        Â
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.Â
Category B: There were lack of studies on pregnant women and no evidence of risk to the foetus in animal experiments.  Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.  Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this category
Pharmacology:Â Â
cyclosporine ophthalmic is a medication used to treat dry eyes. The pharmacology of cyclosporine ophthalmic involves the inhibition of T-cell activation and cytokine release.  Â
 Pharmacodynamics:Â
The pharmacology of cyclosporine ophthalmic involves the inhibition of T-cell activation and cytokine release. Â
Pharmacokinetics: Â
Absorption Â
cyclosporine ophthalmic is a topical medication that is applied directly to the eye. The drug is absorbed through the cornea and into the eye tissue. Â
Distribution Â
cyclosporine is distributed throughout the eye tissue, where it acts locally to reduce inflammation and improve tear production. Â
Metabolism Â
cyclosporine is metabolized in the liver, and some of the metabolites are excreted in the bile. Â
Elimination and Excretion Â
cyclosporine is excreted in the feces and urine, with a small amount being eliminated unchanged in the urine.Â
Administration:Â Â
cyclosporine ophthalmic drops are used to treat dry eyes caused by inflammation. The usual dose is one drop in each eye twice a day, with 12-hour intervals between doses. Before using the medication, wash your hands thoroughly.
Patient information leafletÂ
Generic Name: cyclosporine ophthalmicÂ
Why do we use cyclosporine ophthalmic?Â
cyclosporine ophthalmic is used to treat dry eyes, which is a condition that occurs when the eyes do not produce enough tears or the quality of the tears is poor. This can cause discomfort, irritation, and even damage to the eyes over time.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
